1. Japan Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Kubota Pharmaceutical Holdings Co., Ltd.

Kubota Pharmaceutical Holdings Co., Ltd.

4596.T
Kubota Pharmaceutical Holdings Co., Ltd.JP flagTokyo Stock Exchange
78.00
JPY
-39.00
- -
4.98BMarket Cap
Kubota Pharmaceutical Holdings Co., Ltd.
4596.T
(Tokyo Stock Exchange)

Recent

price

78.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
22.62
- -
- -
- -
0.88
- -
0.17
0.72
0.48
0.33
0.58
Revenue per Share
- -
-104.52
-90.85
-78.42
-73.06
-56.9
-57.46
-40.92
-26.79
-23.65
-10.59
-25.2
Basic EPS, GAAP
- -
-85.79
-87.88
-66.56
-81.47
-52.81
-55.39
-43.53
-25.22
-22.09
-9.3
-24.54
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-103.84
-203.85
-290.61
-351.53
-387.73
-429.54
-458.01
-448.86
-423.23
-444.08
-393.96
-434.45
Book Value per Share
559.96
441.62
342.01
271.41
192.5
139.91
91.2
80.17
47.61
24.66
28.41
36.17
Tangible Book Value per Share
36
37
38
39
42
43
46
49
56
56
64
56
Basic Weighted Avg Shares
- -
846
- -
- -
- -
38
- -
8
40
27
21
32
Sales/Revenue/Turnover
- -
-481.08
- -
- -
- -
-6,573.98
- -
-24,691.3
-3,770.67
-4,948.66
-4,194.31
-4,414.04
Operating Margin (%)
- -
32
29
21
46
45
59
59
87
66
- -
77
Depreciation Expense
- -
-3,911
-3,445
-3,046
-3,066
-2,437
-2,616
-2,016
-1,490
-1,333
-676
-1,414
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-462.12
- -
- -
- -
-6,450.6
- -
-24,423.38
-3,734.56
-4,902.17
-3,169.69
-4,358.35
Profit Margin (%)
13,509
14,302
11,346
10,516
7,672
5,910
4,083
3,821
2,587
1,380
1,812
1,935
Working Capital
- -
- -
103
85
140
180
137
109
87
1
8
64
LT Debt
20,143
16,524
12,967
10,543
8,077
5,993
4,153
3,950
2,647
1,390
1,814
2,029
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
166
176
149
LT Borrowings
- -
- -
- -
LT Finance Leases
87
73
64
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
56
56
56
Market Capitalization
4,433
4,299
4,151

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
2,869
2,556
2,185
Cash, Cash Equivalents & STI
2,768
2,454
2,063
Accounts Receivable, Net
2
1
- -
Inventories
37
49
61
Total Current Liabilities
283
280
249
Payables & Accruals
- -
- -
- -
ST Debt
166
176
149
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-19.3%
-17.11%
30.51%
Free Cash Flow
- -
-20.33%
-52.31%
Net Income, GAAP
- -
-20.3%
-49.26%
Sales/Revenue/Turnover
- -
- -
-21.53%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5
5
- -
- -
27
2025
- -
- -
- -
- -
21
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-6.1
-5.79
- -
- -
-23.65
2025
- -
- -
- -
- -
-10.59
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
MediWound Ltd. (MDWD)
Arcellx, Inc. (ACLX)
Revelation Biosciences, Inc. (REVBW)
EyePoint Pharmaceuticals, Inc. (EYPT)
Cellectis S.A. (ALCLS.PA)
4D Molecular Therapeutics, Inc. (FDMT)
Business
Kubota Pharmaceutical Holdings Co., Ltd. (4596.T) is a clinical-stage biopharmaceutical company focused on developing drugs and medical devices to treat and prevent vision-threatening ophthalmic diseases worldwide. Founded in 2002 through its predecessor Acucela Inc. and headquartered in Tokyo, Japan, the company operates primarily through its subsidiary Kubota Vision Inc. and advances a pipeline targeting conditions such as Stargardt disease, proliferative diabetic retinopathy, age-related macular degeneration, diabetic macular edema, myopia, glaucoma, and dry eye syndrome. Its core products and services include emixustat hydrochloride, an oral visual cycle modulator in Phase 3 for Stargardt disease and Phase 2 for proliferative diabetic retinopathy; Kubota Glass, a wearable myopia-control device approved in Taiwan; a patient-based ophthalmology suite (PBOS) featuring home-based miniature and high-resolution optical coherence tomography (OCT) devices for remote retinal monitoring of neovascular diseases; and additional candidates such as VAP-1 inhibitors, gene therapies for retinitis pigmentosa, and handheld OCT devices for patient self-monitoring. The company serves healthcare providers, patients, and partners in ophthalmology across Japan, the United States, Europe, Asia, and other regions, with research, development, manufacturing, and commercialization activities spanning these markets. In recent developments, Kubota Pharmaceutical Holdings signed sales and distribution agreements for Kubota Glass with Fuhao (China) Optical Technology Co., Ltd. and EverLight Instrument in 2025, expanding commercialization in Asia; entered a basic agreement for capital and business partnership with Acrite CustIntCo Pte Ltd. in Singapore; and announced large-scale exercises of stock acquisition rights, reflecting ongoing capital management efforts. These moves follow prior milestones such as ISO 13485:2016 certification in 2021 and listing transfers on the Tokyo Stock Exchange, underscoring strategic expansions in device distribution and pipeline advancement amid Q3 FY2025 financial reporting.